Temporal control of Ninj1 activation determines cell-to-cell heterogeneity in IL-33 release
Interleukin-33 (IL-33), an IL-1 family cytokine, is released during cell damage. However, the mechanism underlying IL-33 release is not fully understood. Here, we generate IL-33-mCherry-expressing mouse cell lines to monitor IL-33 release at single cell resolution. During necroptosis, SYTOX uptake that represents loss of membrane integrity, and IL-33-mCherry release occur simultaneously, indicating that Mlkl-mediated damage causes immediate membrane rupture. In contrast, some apoptotic and pyroptotic cells exhibit delayed IL-33-mCherry release relative to SYTOX uptake, whereas in other cells, both events occur simultaneously. IL-33-mCherry release is only modestly affected by loss of Gsdmd or Gsdme but is markedly reduced in Ninjurin-1 (Ninj1) knockout cells. These findings indicate that Gasdermins act upstream, whereas Ninj1-mediated membrane rupture represents the principal mechanism of IL-33 release. The delay in IL-33-mCherry release in some cells implies that the activation of Ninj1 occurs with variable timing, thus contributing to cell-to-cell heterogeneity.
Authors
- Hiroyasu Nakano (ORCID: https://orcid.org/0000-0003-4843-1427)
- Yoshitaka Shirasaki (ORCID: https://orcid.org/0000-0002-3808-1630)
- Kenta Sumiyama (ORCID: https://orcid.org/0000-0001-8785-5439)
- Sachiko Komazawa‐Sakon (ORCID: https://orcid.org/0000-0002-6244-1974)
- Takumi Kanokogi (ORCID: https://orcid.org/0000-0001-5901-232X)
- Mai Yamagishi
- Kazuma Kishi
- Shin Murai (ORCID: https://orcid.org/0000-0002-7516-403X)
- Kenta Moriwaki
Institutions
- Hiroshima University (JP)
- Toho University (JP)
- Toho University Omori Medical Center (JP)
- Shanghai Cell Therapy Research Institute (CN)
- Nagoya University (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Communications Biology
- Published
- 2026-05-21
- DOI
- https://doi.org/10.1038/s42003-026-10300-1
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- Princess Takamatsu Cancer Research Fund
- Japan Society for the Promotion of Science
- Core Research for Evolutional Science and Technology